S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

TCRX TScan Therapeutics Inc

8.55

0.26 (3.14%)

May 31 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more TScan Therapeutics Charts.

TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more TScan Therapeutics Charts.

TScan Therapeutics Inc News

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
Thursday 30 May 2024 (3 days ago) • GlobeNewswire Inc.

TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
Wednesday 29 May 2024 (4 days ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Monday 13 May 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 13 May 2024 (3 weeks ago) • Edgar (US Regulatory)

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Monday 13 May 2024 (3 weeks ago) • GlobeNewswire Inc.

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
Thursday 9 May 2024 (3 weeks ago) • GlobeNewswire Inc.

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
Wednesday 24 April 2024 (1 month ago) • GlobeNewswire Inc.

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
Wednesday 24 April 2024 (1 month ago) • GlobeNewswire Inc.

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Monday 22 April 2024 (1 month ago) • GlobeNewswire Inc.

TScan Therapeutics Announces Closing of Upsized Public Offering
Friday 19 April 2024 (1 month ago) • GlobeNewswire Inc.

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
Tuesday 16 April 2024 (2 months ago) • GlobeNewswire Inc.

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering
Tuesday 16 April 2024 (2 months ago) • GlobeNewswire Inc.

More TScan Therapeutics Inc News Articles

Enzolytics (PK)

Kraig Biocraft Laborator... (QB)

Fannie Mae (QB)

Trump Media and Technology

ERHC Energy (CE)

Anavex Life Sciences

CTR Investments and Cons... (CE)

Net Savings Link (PK)

Rennova Health (PK)

Elite Pharmaceuticals (QB)

Lightwave Logic

Branded Legacy (PK)

Voip Pal Com (QB)

Northwest Biotherapeutics (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions